Savara Inc (NASDAQ:SVRA) Receives $9.86 Consensus Target Price from Analysts

Savara Inc (NASDAQ:SVRA - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $9.86.

SVRA has been the subject of several research analyst reports. Wells Fargo & Company started coverage on Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 price objective for the company. HC Wainwright dropped their price target on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Evercore ISI reiterated an "in-line" rating and issued a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday, November 13th. Finally, JMP Securities restated a "market outperform" rating and set a $9.00 target price on shares of Savara in a report on Thursday, December 19th.

Savara Price Performance

Shares of NASDAQ SVRA traded down $0.01 during trading on Wednesday, hitting $3.07. 390,335 shares of the company were exchanged, compared to its average volume of 1,264,216. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara has a 1 year low of $2.82 and a 1 year high of $5.70. The company has a market cap of $526.87 million, a price-to-earnings ratio of -7.14 and a beta of 0.92. The firm's fifty day moving average price is $3.40 and its 200 day moving average price is $3.93.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). On average, sell-side analysts expect that Savara will post -0.45 earnings per share for the current fiscal year.

Insider Activity at Savara

In related news, CEO Matthew Pauls sold 54,702 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.31, for a total transaction of $181,063.62. Following the sale, the chief executive officer now owns 1,536,379 shares in the company, valued at approximately $5,085,414.49. This trade represents a 3.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph S. Mccracken purchased 20,000 shares of the business's stock in a transaction on Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the acquisition, the director now directly owns 210,837 shares in the company, valued at $621,969.15. The trade was a 10.48 % increase in their position. The disclosure for this purchase can be found here. 5.13% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Savara

Hedge funds have recently made changes to their positions in the business. Choreo LLC acquired a new stake in Savara in the 2nd quarter worth about $59,000. DRW Securities LLC acquired a new stake in shares of Savara in the second quarter worth approximately $62,000. Virtu Financial LLC purchased a new stake in Savara in the third quarter valued at approximately $67,000. Principal Financial Group Inc. increased its position in Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company's stock worth $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC purchased a new position in Savara during the second quarter worth approximately $105,000. Institutional investors and hedge funds own 87.93% of the company's stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.